{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Adverse events reported as possibly, probably, or definitely related to treatment are considered to be treatment-related adverse events.","groups":[{"description":"\\[As-treated\\]\n\nSTEP 1 (all patients): Patients who received allowed neoadjuvant systemic therapy before study entry undergo pleurectomy/decortication (P/D) within 4 to 8 weeks of systemic therapy. Otherwise, patients undergo P/D within 4 weeks of study entry followed within 4 to 8 weeks by four 21-day cycles of pemetrexed and cisplatin or carboplatin on day 1.\n\nSTEP 2 (randomized): Patients receive no treatment.","id":"OG000","title":"Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment)"},{"description":"\\[As-treated\\]\n\nSTEP 1 (all patients): Same as Arm 1.\n\nSTEP 2 (randomized): Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions of intensity modulated radiation therapy (IMRT) or pencil beam scanning (PBS) proton therapy 5 days/week over 6 weeks.","id":"OG001","title":"Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomized patients who received protocol treatment and were assessed for adverse events. Arms determined by Step 2 treatment received (as-treated).","reportingStatus":"POSTED","timeFrame":"From randomization to death or last follow-up. Maximum follow-up time was 25 months.","title":"Number of Patients With Grade 3 or Higher Treatment-related Adverse Event After Randomization","type":"SECONDARY","unitOfMeasure":"Participants"}